Skip to main content

Table 3 Prognostic significance of sEV-derived ncRNAs in PDAC

From: Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

Reference Sample sEV Isolation Normalization ncRNA Tumor type Patients by UICC stage Effect UVA MVA
I IIA IIB III IV
Mikamori et al. [127] Plasma EQ cel-miR-39 miR-155 PDAC 23 High expression correlated with shorter DFS
Takahasi et al. [175] Plasma UC miR-16a miR-451a PDAC 7 43 High expression correlated with shorter DFS/OS
Goto et al. [145] Serum EQ not specified miR-21 all PC 2 7 4 5 14 High expression correlated with shorter OS (344 days vs. 846 days)
Li et al. [53] Plasma EQ RNU6, β-actin mRNA lncSox2ot PDAC 28 28 High expression correlated with shorter OS (12 months vs. 15 months)
Li et al. [47] Plasma EQ RNU6, β-actin mRNA circPDE8A PDAC 47 40 High expression correlated with shorter OS (13 months vs. 16 months)
Wang et al. [84] Serum TEI cel-miR-39 miR-301a-3p all PC 20 30 High expression correlated with shorter OS
Li et al. [57] Plasma TEI not specified circIARS PDAC 42 39 High expression correlated with shorter OS (11 months vs. 16 months)
Li et al. [49] Plasma EQ not specified miR-222 PDAC 39 34 High expression correlated with shorter OS (10 months vs. 17 months)
Kawamura et al. [161] PVB UC cel-miR-39, miR-16 miRs 21, 451a, 4525 PDAC 4 27 24 High expression correlated with shorter DFS/OS
Reese et al. [155] Serum UC cel-miR-39 miR-200c PDAC 4 14 22 16 High expression correlated with shorter OS (miR-200c: 11 months vs. 18 months) (miR-200b: 9 months vs. 18 months)
miR-200b
Guo et al. [116] Serum EQ β-actin lncUCA1 all PC 20 26 High expression correlated with shorter OS
Shao et al Serum EQ cel-miR-39 miR-483-3p PDAC 18 37 6 2 High expression correlated with shorter OS
Nishiwada et al. [176]   Plasma/Serum TEI miR-16 6 miR-panel (130b-5p, 133a-3p, 195-5p, 432-5p, 1229-3p, 1273f) PDAC 3 8 14 Discovery cohort
“high risk” correlated with shorter RfS
9 12 33 26 2 Training cohort
“high risk” correlated with shorter RfS
3 22 31 1 Validation cohort I (did not receive NAT)
“high risk” correlated with shorter RfS
10 21 13 2 Validation cohort II (received NAT)
“high risk” correlated with shorter RfS
  1. cel, Caenorhabditis elegans; DFS, disease-free survival; EQ, ExoQuick (SystemBiosciences); MVA, multivariate survival analysis; n, number of patients; NAT, neoadjuvant therapy; OS, overall survival; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PVB, portal vein blood; TEI, Total Exosome Isolation Kit (ThermoFisher); UC, ultracentrifugation; UVA, univariate survival analysis